Starphama share price lunges 5% on product relaunch

Early support for Starphama on Thursday has it off to a great start.

| More on:
Rising arrow on a blue graph symbolising a rising share price.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Starpharma is set to relaunch Viraleze in the UK 
  • Sales of the product were paused last year as the company and its distributor responded to issues raised by the UK regulator 
  • In the last 12 months, the Starpharma share price has slipped more than 53% into the red 

The Starpharma Holdings Ltd (ASX: SPL) share price has jumped out of the gates and is trading higher on Thursday.

At the time of writing, investors are bidding Starpharma 5% higher to 70 cents apiece.

Support comes following a company announcement on sales of its Viraleze label in the UK after a temporary pause.

What did Starpharma announce?

The company advised that its Viraleze nasal spray has been relaunched by LloydsPharmacy in the UK.

According to Starpharma, the Viraleze nasal spray physically traps and blocks cold/respiratory viruses in the nasal cavity. It is registered in over 30 countries but is not approved for sale or supply in Australia.

Sales of the product were paused in the UK back in 2021. It was to address correspondence from the UK Medicines and Healthcare products Regulatory Agency (MHRA) in relation to promotional claims.

After successful resolution of the issues raised, Viraleze is now ready to be stacked back onto UK shelves.

The relaunch will see Starpharma supply LloydsPharmacy exclusively with Viraleze under its existing sales and distribution agreement.

Management commentary

Speaking on the announcement, CEO of Starpharma, Dr Jackie Fairley said:

We are delighted to relaunch Starpharma’s innovative nasal spray, Viraleze, in the UK through LloydsPharmacy’s extensive online and retail network. Viraleze will be particularly useful in the winter cold and flu season given its broad-spectrum of activity against multiple cold and respiratory viruses. Viraleze is supported by multiple publications in peer-reviewed, international journals and was presented at leading, international antiviral conference, CROI, earlier this year.

In the last 12 months, the Starpharma share price has slipped more than 53% into the red.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Starpharma Holdings Limited. The Motley Fool Australia has recommended Starpharma Holdings Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Five healthcare workers standing together and smiling.
Healthcare Shares

Medibank share price dips despite dividend boost

The healthcare insurer will pay its biggest final dividend since 2019.

Read more »

Three medical staffers sit at a table and chat happily wearing hospital scrubs
Earnings Results

Pro Medicus share price fails to fly on 44% profit leap

Here's how Pro Medicus dialled up the profits in FY22.

Read more »

A CSL scientist looking through a telescope in a lab
Earnings Results

Telix share price slides despite 726% revenue boost

Investors may be thinking the pharmaceutical company's valuation has peaked after the stock price doubled over the past three months.

Read more »

Broker looking at the share price on her laptop with green and red points in the background.
Broker Notes

Broker gives its verdict on the CSL share price post-FY22 results

Here's what this broker is saying about the CSL share price...

Read more »

An older woman tries to listen by cupping her ear.
Healthcare Shares

Guess which ASX biotech share is soaring 32% on a ‘landmark’ FDA ruling

What a day it has become for this small-cap healthcare company.

Read more »

Two happy scientists analysing test results.
Dividend Investing

Everything you need to know about the latest CSL dividend

Own CSL shares? Here's the details regarding its latest dividend.

Read more »

A businesswoman exhales a deep sigh after receiving bad news, and gets on with it.
Healthcare Shares

CSL share price drops despite expectations of growth in FY23

Investors are punishing CSL. What's going on?

Read more »

ventilator mask
Healthcare Shares

Why ‘the outlook is very bullish’ for the Resmed share price: Tribeca

ResMed has been rated as a buy by Tribeca.

Read more »